Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Souders Financial Advisors

Souders Financial Advisors trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 36.2% in the 4th quarter, Holdings Channel.com reports. The fund owned 489 shares of the biopharmaceutical company’s stock after selling 278 shares during the quarter. Souders Financial Advisors’ holdings in Regeneron Pharmaceuticals were worth $348,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Howe & Rusling Inc. grew its position in shares of Regeneron Pharmaceuticals by 3.4% in the third quarter. Howe & Rusling Inc. now owns 462 shares of the biopharmaceutical company’s stock valued at $486,000 after purchasing an additional 15 shares during the period. Willner & Heller LLC grew its position in shares of Regeneron Pharmaceuticals by 3.9% in the fourth quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company’s stock valued at $284,000 after purchasing an additional 15 shares during the period. OLD Second National Bank of Aurora grew its position in shares of Regeneron Pharmaceuticals by 0.5% in the fourth quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company’s stock valued at $2,025,000 after purchasing an additional 15 shares during the period. Sigma Planning Corp grew its position in shares of Regeneron Pharmaceuticals by 4.1% in the third quarter. Sigma Planning Corp now owns 409 shares of the biopharmaceutical company’s stock valued at $430,000 after purchasing an additional 16 shares during the period. Finally, GLOBALT Investments LLC GA grew its position in shares of Regeneron Pharmaceuticals by 1.5% in the third quarter. GLOBALT Investments LLC GA now owns 1,067 shares of the biopharmaceutical company’s stock valued at $1,122,000 after purchasing an additional 16 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

REGN has been the topic of several research analyst reports. Truist Financial dropped their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. BMO Capital Markets lowered their price target on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 4th. Bernstein Bank lowered their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Bank of America restated an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Finally, Robert W. Baird lowered their price target on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $687.15 on Thursday. The company’s 50 day simple moving average is $696.58 and its 200-day simple moving average is $857.92. The company has a market capitalization of $75.12 billion, a price-to-earnings ratio of 17.95, a price-to-earnings-growth ratio of 2.34 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business’s revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm earned $11.86 EPS. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.51%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.